Unaudited Statement News Today

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24...

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies expected in the coming months Cash runway...

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies...

Research and Development - General and Administrative 4,321,718 431,103 52,148 Selling Expenses 228,165 13,808-Operating Taxes 28,649 - Other Operating Expenses -- Total Operating Expenses 3,314,185...

UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology, Inc. § Case No. 22-11292 § § Lead Case No. 22-11292 Debtor § Jointly Administered... | June 10, 2023

Expands pipeline with acquisition of new tri-specific antibodiesData readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple

BH Macro Limited - Interim Report and Unaudited Financial Statements 2022 PR Newswire London, September 9 BH Macro Limited Interim Report and Unaudited Financial Statements 2022 LEI:

REHOVOT, Israel, Aug. 04, 2022 -- Purple Biotech Ltd. , a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to... | August 4, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

DJ Samarkand Group plc: Interim Results Samarkand Group plc (SMK) Samarkand Group plc: Interim Results 16-Dec-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group.